# A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer

> **NCT05567185** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 5 (actual)

## Conditions studied

- Urinary Bladder Neoplasms
- Receptors, Fibroblast Growth Factor

## Interventions

- **DRUG:** Erdafitinib Intravesical Delivery System

## Key facts

- **NCT ID:** NCT05567185
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-03-03
- **Primary completion:** 2025-03-11
- **Final completion:** 2026-08-30
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05567185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05567185, "A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer". Retrieved via AI Analytics 2026-08-15 from https://api.ai-analytics.org/clinical/NCT05567185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*